Article
Clearing of circulating tumour DNA predicts clinical response to first line tyrosine kinase inhibitors in advanced epidermal growth factor receptor mutated non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) - 1 Mar 2020
Ebert Eva Boysen Fynboe, McCulloch Tine, Hansen Karin Holmskov, Linnet Hanne, Sorensen Boe, Meldgaard Peter
Abstract excerpt
OBJECTIVES: Epidermal growth factor receptor (EGFR) mutations confer sensitivity to tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC). However, a subset of patients has limited or no response. We investigated the initial dynamics of EGFR mutations detected in circulating tumour DNA (ctDNA) during treatment as a predictive marker of outcome. METHODS: A total of 225 patients with advanced EGFR...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.